Skip to search formSkip to main contentSkip to account menu

Anti-CD123 Monoclonal Antibody CSL362

Known as: Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362, CSL362 
A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
THU0311 IL3R-Alpha as A Novel Therapeutic Target in Systemic Lupus Erythematosus
Background Despite currently available therapies, a significant morbidity, and mortality remains in SLE. Major therapeutic… 
2016
2016
OP0041 JNJ-473 Potently and Specifically Depletes PDCS In SLE Patient Blood In Vitro and Ablates TLR9-Induced Interferon Alpha Responses
Background Plasmacytoid dendritic cells (pDCs) are potent producers of IFNα and are thought to have a pathogenic role in Systemic… 
Review
2015
Review
2015
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
2015
2015
Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)
Background AML patients (pts) who achieve a morphologic complete remission (CR) may have MRD in bone marrow (BM) and/or… 
2014
2014
Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362.
Interleukin-3 (IL-3) is a member of the beta common family of cytokines that regulate multiple functions of myeloid cells. The IL… 
2014
2014
depletes CML progenitor and stem cells with CSL362 effectively α Monoclonal antibody targeting of IL-3 receptor
2012
2012
Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor
Abstract 1524 CSL362, a novel humanized, affinity matured monoclonal antibody (mAB), is currently under development at CSL… 
2012
2012
A Neutralizing Antibody (CSL362) Against the Interleukin-3 Receptor α-Chain Augments the Efficacy of a Cytarabine/Daunorubicin Induction-Type Therapy in Preclinical Xenograft Models of Acute…
Abstract 3599 Introduction: Despite the development of many new agents for the treatment of acute myelogenous leukemia (AML), the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)